How it works
Branched DNA (bDNA) technology is a widely used clinical platform to quantitatively detect specific nucleic acid sequences directly from source without DNA/RNA purification or RT-PCR. bDNA quantitative hybridization technology has a wide dynamic range and is sensitive enough for applications intended to reliably detect very few target molecules. bDNA technology has several advantages over PCR technology and is commonly used for applications requiring a high degree of specificity and sensitivity.
Because the basic method is not dependent on reverse transcription and geometric amplification of the target, bDNA assays are consequently not susceptible to contamination risks associated with most PCR-based assays. Furthermore, sensitivity, linearity accuracy and precision, and therefore reliability, of bDNA assays is superior to PCR assays making bDNA the ideal platform for companion diagnostic development of mRNA and microRNA biomarkers as well as DNA copy number variations and DNA polymorphisms.
DiaCarta offers the SuperbDNA™ total solution including kits, reagents and Luminometer, all developed under GMP quality management system for DNA or RNA detections of cancer biomarkers, bacteria, fungi and virus (with over 4000 genes available).